Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
Completed
Glenmark Specialty S.A.
Phase 3
2016-08-01
Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo
NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis
(subjects 12 years of age and older)
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
Completed
Glenmark Pharmaceuticals Ltd. India
Phase 2
2014-01-27
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and
mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects
with seasonal allergic rhinitis. In this study, the efficacy and safety of two regimens (BID
and QD) of the FDC (i.e. Molo 1 and Molo 2) were evaluated compared to placebo nasal spray,
DYMISTA® and PATANASE®.
Azelastine Allergen Chamber - Onset of Action Study
Completed
MEDA Pharma GmbH & Co. KG
Phase 2
2023-10-30
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in
treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen
challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day
treatment at home.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
